无菌性脓疱病研究进展

doi:10.3760/cma.j.issn.0412-4030.2018.12.021

摘要/Abstract

摘要： 无菌性脓疱病系非感染性非毛囊性脓疱病，临床表现为脓疱、发热、全身炎症反应。分为泛发型及局限型，泛发型包括全身泛发性脓疱性银屑病（GPP）、急性泛发性发疹性脓疱病（AGEP）、角层下脓疱病（SPD）、自身炎症性脓疱病；局限型包括掌跖脓疱病、连续性肢端皮炎（ACH）、SAPHO综合征（滑膜炎、痤疮、脓疱病、骨肥厚、骨髓炎综合征）、皱褶部位无菌性脓疱病（amicrobial pustulosis of the folds，APF）……

阮叶平郑捷. 无菌性脓疱病研究进展[J]. 中华皮肤科杂志, 2018, 51(12): 916-919.

Ruan Yeping, Zheng Jie. Amicrobial pustulosis: an update[J]. Chinese Journal of Dermatology, 2018, 51(12): 916-919.

参考文献 45

［1］	Augey F, Renaudier P, Nicolas JF. Generalized pustular psoriasis （Zumbusch）: a French epidemiological survey［J］. Eur J Dermatol, 2006,16（6）:669⁃673.
［2］	Ohkawara A, Yasuda H, Kobayashi H, et al. Generalized pustular psoriasis in Japan: two distinct groups formed by differences in symptoms and genetic background［J］. Acta Derm Venereol, 1996,76（1）:68⁃71.
［3］	Sidoroff A, Dunant A, Viboud C, et al. Risk factors for acute generalized exanthematous pustulosis （AGEP）⁃results of a multinational case⁃control study （EuroSCAR）［J］. Br J Dermatol, 2007,157（5）:989⁃996. doi: 10.1111/j.1365⁃2133.2007.08156.x.
［4］	Watts PJ, Khachemoune A. Subcorneal pustular dermatosis: a review of 30 years of progress［J］. Am J Clin Dermatol, 2016,17（6）:653⁃671. doi: 10.1007/s40257⁃016⁃0202⁃8.
［5］	Naik HB, Cowen EW. Autoinflammatory pustular neutrophilic diseases［J］. Dermatol Clin, 2013,31（3）:405⁃425. doi: 10.1016/j.det.2013.04.001.
［6］	Aksentijevich I, s SL, Ferguson PJ, et al. An autoinflam⁃matory disease with deficiency of the interleukin⁃1⁃receptor antagonist［J］. N Engl J Med, 2009,360（23）:2426⁃2437. doi: 10. 1056/NEJMoa0807865.
［7］	Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin⁃36⁃receptor antagonist deficiency and generalized pustular psoriasis［J］. N Engl J Med, 2011,365（7）:620⁃628. doi: 10.1056/NEJMoa 1013068.
［8］	Jordan CT, Cao L, Roberson ED, et al. Rare and common variants in CARD14, encoding an epidermal regulator of NF⁃kappaB, in psoriasis［J］. Am J Hum Genet, 2012,90（5）:796⁃808. doi: 10. 1016/j.ajhg.2012.03.013.
［9］	Wang MZ, Camilleri MJ, Guo R, et al. Amicrobial pustulosis of the folds: report of 4 cases［J］. J Cutan Pathol, 2017,44（4）:367⁃372. doi: 10.1111/cup.12873.
［10］	Sugiura K. The genetic background of generalized pustular psoriasis: IL36RN mutations and CARD14 gain⁃of⁃function variants［J］. J Dermatol Sci, 2014,74（3）:187⁃192. doi: 10.1016/j.jdermsci.2014.02.006.
［11］	Johnston A, Xing X, Wolterink L, et al. IL⁃1 and IL⁃36 are dominant cytokines in generalized pustular psoriasis［J］. J Allergy Clin Immunol, 2017,140（1）:109⁃120. doi: 10.1016/j.jaci. 2016.08.056.
［12］	Feldmeyer L, Heidemeyer K, Yawalkar N. Acute generalized exanthematous pustulosis: pathogenesis, genetic background, clinical variants and therapy［J］. Int J Mol Sci, 2016,17（8）:1214. doi: 10.3390/ijms17081214.
［13］	Szatkowski J, Schwartz RA. Acute generalized exanthematous pustulosis （AGEP）: a review and update［J］. J Am Acad Dermatol, 2015,73（5）:843⁃848. doi: 10.1016/j.jaad.2015.07.017.
［14］	Barbaud A, Collet E, Milpied B, et al. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions［J］. Br J Dermatol, 2013,168（3）:555⁃562. doi: 10.1111/bjd.12125.
［15］	Kabashima R, Sugita K, Sawada Y, et al. Increased circulating Th17 frequencies and serum IL⁃22 levels in patients with acute generalized exanthematous pustulosis［J］. J Eur Acad Dermatol Venereol, 2011,25（4）:485⁃488. doi: 10.1111/j.1468⁃3083.2010. 03771.x.
［16］	Kakeda M, Schlapbach C, Danelon G, et al. Innate immune cells express IL⁃17A/F in acute generalized exanthematous pustulosis and generalized pustular psoriasis［J］. Arch Dermatol Res, 2014,306（10）:933⁃938. doi: 10.1007/s00403⁃014⁃1488⁃0.
［17］	Navarini AA, Simpson MA, Borradori L, et al. Homozygous missense mutation in IL36RN in generalized pustular dermatosis with intraoral involvement compatible with both AGEP and generalized pustular psoriasis［J］. JAMA Dermatol, 2015,151（4）:452⁃453. doi: 10.1001/jamadermatol.2014.3848.
［18］	Ono S, Otsuka A, Miyachi Y, et al. Subcorneal pustular dermatosis exhibiting a high serum TARC/CCL17 level［J］. Case Rep Dermatol, 2013,5（1）:38⁃42. doi: 10.1159/000348241.
［19］	Jesus AA, Goldbach⁃Mansky R. IL⁃1 blockade in autoinflam⁃matory syndromes［J］. Annu Rev Med, 2014,65:223⁃244. doi: 10. 1146/annurev⁃med⁃061512⁃150641.
［20］	Foster AM, Baliwag J, Chen CS, et al. IL⁃36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin［J］. J Immunol, 2014,192（12）:6053⁃6061. doi: 10.4049/jimmunol. 1301481.
［21］	Blumberg H, Dinh H, Trueblood ES, et al. Opposing activities of two novel members of the IL⁃1 ligand family regulate skin inflammation［J］. J Exp Med, 2007,204（11）:2603⁃2614. doi: 10. 1084/jem.20070157.
［22］	Tauber M, Bal E, Pei XY, et al. IL36RN mutations affect protein and function: a basis for genotype⁃phenotype correlation in pustular diseases［J］. J Invest Dermatol, 2016,136（9）:1811⁃1819. doi: 10.1016/j.jid.2016.04.038.
［23］	Berki DM, Liu L, Choon SE, et al. Activating CARD14 mutations are associated with generalized pustular psoriasis but rarely account for familial recurrence in psoriasis vulgaris［J］. J Invest Dermatol, 2015,135（12）:2964⁃2970. doi: 10.1038/jid.2015. 288.
［24］	Takeichi T, Kobayashi A, Ogawa E, et al. Autosomal dominant familial generalized pustular psoriasis caused by a CARD14 mutation［J］. Br J Dermatol, 2017,177（4）:e133⁃e135. doi: 10.1111/bjd.15442.
［25］	Mössner R, Frambach Y, Wilsmann⁃Theis D, et al. Palmoplantar pustular psoriasis is associated with missense variants in CARD14, but not with loss⁃of⁃function mutations in IL36RN in European patients［J］. J Invest Dermatol, 2015,135（10）:2538⁃2541. doi: 10.1038/jid.2015.186.
［26］	Bissonnette R, Fuentes⁃Duculan J, Mashiko S, et al. Palmoplantar pustular psoriasis （PPPP） is characterized by activation of the IL⁃17A pathway［J］. J Dermatol Sci, 2017,85（1）:20⁃26. doi: 10.1016/ j.jdermsci.2016.09.019.
［27］	Abbas O, Itani S, Ghosn S, et al. Acrodermatitis continua of Hallopeau is a clinical phenotype of DITRA: evidence that it is a variant of pustular psoriasis［J］. Dermatology, 2013,226（1）:28⁃31. doi: 10.1159/000346572.
［28］	Firinu D, Garcia⁃Larsen V, Manconi PE, et al. SAPHO syndrome: current developments and approaches to clinical treatment［J］. Curr Rheumatol Rep, 2016,18（6）:35. doi: 10.1007/s11926⁃016⁃0583⁃y.
［29］	Marzano AV, Cugno M, Trevisan V, et al. Inflammatory cells, cyto⁃kines and matrix metalloproteinases in amicrobial pustulosis of the folds and other neutrophilic dermatoses［J］. Int J Immunopathol Pharmacol, 2011,24（2）:451⁃460. doi: 10.1177/039463201102400 218.
［30］	Bolognia JL, Jorizzo JL, Rapini RP. 皮肤病学［M］. 朱学俊, 王宝玺, 孙建方, 等, 译. 2版. 北京: 北京大学医学出版社, 2011: 1543.
［31］	Reddy S, Jia S, Geoffrey R, et al. An autoinflammatory disease due to homozygous deletion of the IL1RN locus［J］. N Engl J Med, 2009,360（23）:2438⁃2444. doi: 10.1056/NEJMoa0809568.
［32］	Robinson A, Van Voorhees AS, Hsu S, et al. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation［J］. J Am Acad Dermatol, 2012,67（2）:279⁃288. doi: 10.1016/j.jaad.2011.01.032.
［33］	Teoh YL, Tay YK. Generalized pustular psoriasis with a novel mutation of interleukin⁃36 receptor antagonist, responding to methotrexate［J］. JAAD Case Rep, 2015,1（2）:51⁃53. doi: 10.1016/ j.jdcr.2014.12.007.
［34］	Koike Y, Okubo M, Kiyohara T, et al. Granulocyte and monocyte apheresis can control juvenile generalized pustular psoriasis with mutation of IL36RN［J］. Br J Dermatol, 2017,177（6）:1732⁃1736. doi: 10.1111/bjd.15509.
［35］	Sevrain M, Richard MA, Barnetche T, et al. Treatment for palmoplantar pustular psoriasis: systematic literature review, evidence⁃based recommendations and expert opinion［J］. J Eur Acad Dermatol Venereol, 2014,28 Suppl 5:13⁃16. doi: 10.1111/jdv. 12561.
［36］	Bordignon M, Zattra E, Albertin C, et al. Successful treatment of a 9⁃year⁃old boy affected by acrodermatitis continua of Hallopeau with targeted ultraviolet B narrow⁃band phototherapy［J］. Photodermatol Photoimmunol Photomed, 2010,26（1）:41⁃43. doi: 10.1111/j.1600⁃0781.2009.00468.x.
［37］	Schissler C, Velter C, Lipsker D. Amicrobial pustulosis of the folds: where have we gone 25 years after its original description?［J］. Ann Dermatol Venereol, 2017,144（3）:169⁃175. doi: 10.1016/ j.annder.2016.10.018.
［38］	Pan J, Qiu L, Xiao T, et al. Juvenile generalized pustular psoriasis with IL36RN mutation treated with short⁃term infliximab［J］. Dermatol Ther, 2016,29（3）:164⁃167. doi: 10.1111/dth.12325.
［39］	Arakawa A, Ruzicka T, Prinz JC. Therapeutic efficacy of interleukin 12/interleukin 23 blockade in generalized pustular psoriasis regardless of IL36RN mutation status［J］. JAMA Dermatol, 2016,152（7）:825⁃828. doi: 10.1001/jamadermatol.2016. 0751.
［40］	Cymerman RM, Cohen DE. Treatment of acrodermatitis continua of hallopeau with ustekinumab as monotherapy［J］. JAMA Dermatol, 2016,152（3）:346⁃348. doi: 10.1001/jamadermatol.2015. 3444.
［41］	Wenk KS, Claros JM, Ehrlich A. Flare of pustular psoriasis after initiating ustekinumab therapy［J］. J Dermatolog Treat, 2012,23（3）:212⁃214. doi: 10.3109/09546634.2010.534430.
［42］	Khemis A, Cavalié M, Montaudié H, et al. Rebound pustular psoriasis after brodalumab discontinuation［J］. Br J Dermatol, 2016,175（5）:1065⁃1066. doi: 10.1111/bjd.14627.
［43］	Hüffmeier U, Wätzold M, Mohr J, et al. Successful therapy with anakinra in a patient with generalized pustular psoriasis carrying IL36RN mutations［J］. Br J Dermatol, 2014,170（1）:202⁃204. doi: 10.1111/bjd.12548.
［44］	Lutz V, Lipsker D. Acitretin⁃ and tumor necrosis factor inhibitor⁃resistant acrodermatitis continua of hallopeau responsive to the interleukin 1 receptor antagonist anakinra［J］. Arch Dermatol, 2012,148（3）:297⁃299. doi: 10.1001/archdermatol.2011.2473.
［45］	Saggini A, Chimenti S, Chiricozzi A. IL⁃6 as a druggable target in psoriasis: focus on pustular variants［J］. J Immunol Res, 2014,2014:964069. doi: 10.1155/2014/964069.

无菌性脓疱病研究进展

Amicrobial pustulosis: an update

PDF

赞

可视化

摘要/Abstract

引用本文

使用本文

参考文献 45

相关文章 0

Metrics

本文评价

推荐阅读 10